# H11-BIOPHARMACEUTICA: Biopharmaceuticals Agent

## Overview
The H11-BIOPHARMACEUTICA agent focuses on the design, production, and analysis of large-molecule drugs, including monoclonal antibodies (mAbs), recombinant proteins, and biosimilars. It handles complex workflows from protein engineering and expression optimization to downstream processing and formulation stability.

## Architecture
- **Protein Engineering Module**: Evaluates sequence liabilities (e.g., deamidation, oxidation sites) and binding affinity predictions.
- **Bioprocessing Simulator**: Models cell culture growth (upstream) and chromatography purification steps (downstream).
- **Formulation Predictor**: Uses biophysical descriptors to predict aggregation propensity and long-term stability under varied thermal conditions.

## Interfaces
- Input: Protein sequences (FASTA), expression system parameters, formulation excipient lists.
- Output: Biomanufacturing protocols, liability reports, stability indices, and biosimilarity scores.

## Algorithms
- **Sequence Liability Scanning**: Pattern matching and structural context evaluation for post-translational modification risks.
- **Monod Kinetics**: Simulates CHO cell growth and antibody titer production.
- **Aggregation Kinetics Model**: Lumry-Eyring framework for predicting protein unfolding and aggregation over time.
